A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
Launched by ELI LILLY AND COMPANY · Nov 8, 2019
Trial Information
Current as of June 13, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must agree to use appropriate birth control throughout the study
- • Must have a diagnosis of CSU for at least 6 months
- • Must have CSU symptoms for at least 8 consecutive weeks despite taking anti-histamines
- • Must agree to take an anti-histamine every day during the trial
- • Must be willing to enter information about symptoms in an electronic diary twice a day
- Exclusion Criteria:
- • Must not have a cause, other than CSU, for itching, hives, and/or angioedema (swelling beneath the skin)
- • Must not have a current or recent active infection requiring antibiotics
- • Must not have a history of anaphylaxis (severe, life threatening allergic reaction)
- • Must not have asthma requiring medications other than short acting beta agonists (albuterol, etc.)
- • Must not have received prior treatment with omalizumab, ligelizumab, or other experimental biologic for CSU
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Columbus, Ohio, United States
Tulsa, Oklahoma, United States
Redwood City, California, United States
Sarasota, Florida, United States
Berlin, , Germany
Mainz, Rheinland Pfalz, Germany
Münster, Nordrhein Westfalen, Germany
Berlin, , Germany
Lancaster, California, United States
Fountain Valley, California, United States
Warszawa, Mazowieckie, Poland
Boise, Idaho, United States
Hannover, Niedersachsen, Germany
Tampa, Florida, United States
Krakow, Malopolskie, Poland
Miami, Florida, United States
Portland, Oregon, United States
Bakersfield, California, United States
Tampa, Florida, United States
Los Angeles, California, United States
Aventura, Florida, United States
Miami, Florida, United States
Owensboro, Kentucky, United States
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials